Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. - Wikidata - wikimedia - TriplyDB

Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity.

Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity.

http://www.wikidata.org/entity/Q31009736

about

Delivery of oligonucleotides with lipid nanoparticles Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells Physico-chemical characteristics of lipoplexes influence cell uptake mechanisms and transfection efficacy Microsomal epoxide hydrolase of rat liver is a subunit of theanti-oestrogen-binding site Origins, structures, and functions of circulating DNA in oncology Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides.Quantitative nuclear and cytoplasmic localization of antisense oligonucleotides by capillary electrophoresis with laser-induced fluorescence detection.Inhibition of the human chemokine receptor CXCR4 by antisense phosphorothioate oligodeoxyribonucleotides.Systemic gene therapy: biodistribution and long-term expression of a transgene in mice.Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay.Ofloxacin-loaded liposomes: in vitro activity and drug accumulation in bacteria.Delivery of novel macromolecular drugs against HIV-1.Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms.Lysine: Is it worth more?Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies Radiolabeled oligonucleotides for antisense imaging.Liposomal nanomedicine for breast cancer therapy.Canonical and non-canonical barriers facing antimiR cancer therapeutics Lipid-based delivery of CpG oligodeoxynucleotides for cancer immunotherapy.Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects.Suppression of glioblastoma cell growth following antisense oligonucleotide-mediated inhibition of fibroblast growth factor receptor expression.Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus.Inhibition of luciferase expression by synthetic hammerhead ribozymes and their cellular uptake Biological availability and nuclease resistance extend the in vitro activity of a phosphorothioate-3'hydroxypropylamine oligonucleotide.Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells.Synthesis and hybridization properties of oligonucleotides containing 2'-O-modified ribonucleotides.Inhibition of inositol uptake in astrocytes by antisense oligonucleotides delivered by pH-sensitive liposomes.Specific inhibition of human telomerase activity by transfection reagent, FuGENE6-antisense phosphorothioate oligonucleotide complex in HeLa cells.Antisense oligodeoxynucleotides as clinical therapeutic agents.Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by liposomally encapsulated antisense phosphorothioate oligonucleotides in MDCK cells.Effect of unmodified triple helix-forming oligodeoxyribonucleotide targeted to human multidrug-resistance gene mdr1 in MDR cancer cells.Influence of lipoplex surface charge on siRNA delivery: application to the in vitro downregulation of CXCR4 HIV-1 co-receptor.Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A.

P2860

Q27024646-E5E56BDE-0ADF-4D2F-A63B-01185F2B78A1 Q28369354-BDE62172-0DAB-45E2-9689-DF662794F7D9 Q28475692-8FAF9B6D-5AD2-48DA-8D0D-392647909C4F Q28568639-69D0D569-AF7A-4C45-BB41-CB774F6D2DA2 Q30249103-47A87BAE-B42F-47ED-82A5-2B7FBFA83A73 Q30453773-AB670437-9F50-45F4-84B3-C56D784D774D Q30667117-52F9C2C2-3186-40DA-8475-A0B0741D04CE Q31864643-C74F11F7-9FFF-42D7-9768-F5BC25A712C3 Q33867700-ABB90BCD-8550-4CDD-8FD4-4BB166959822 Q33970193-94597C70-F6C0-4CF4-A561-EA8AC022F080 Q33980505-CAE3C49C-58EF-4FF7-8ACE-C65D034121A3 Q34452681-314D6B13-1354-4482-BDC7-165449073924 Q35858474-9145D836-3055-4FF7-B2EB-0C94407A6424 Q35870795-7DDA5897-9A85-49F0-99CF-D7789BA42C04 Q36254989-3539BAED-8738-4F4E-8E51-5F3F8898D7B5 Q36868031-0F525CBD-E692-41AF-A3A2-AD854F7C6C6A Q37913042-F281BB43-2B43-403E-9EA2-363AC0BC1B8A Q37939968-565A7624-7D5A-40B6-9778-8F41DC3BCC33 Q38112723-FCAB9D72-0A89-45B2-9A10-C7791C6D9C11 Q38177364-10894DB4-0919-405E-95F6-85B4885B634D Q38315868-71C2B6DD-71E7-4E46-BAFF-C27100FA80F9 Q38320161-B080DABF-0704-4412-BCA1-5982C6E58024 Q39723515-98F0E055-7795-4F52-81CC-B8362D9F936A Q39728591-49A4DD76-0294-4E93-A0F7-C0A833582E04 Q40398950-D63E2911-F04F-4832-88BA-1F2DF7F69DAE Q40409131-06A9CC81-9FF9-4D14-87C6-660CE3F9B218 Q40415620-87F379D8-8989-44AB-B535-AF4FF6751B9A Q40887907-F29FBA4D-DC2F-4BDC-876B-FCE043FCB0B6 Q40938167-89C742DA-95A7-4EFD-927D-E9794DD54506 Q40968139-9A1C4A1B-069C-4A8B-8414-5229B6EB463B Q40983867-0431C935-70EE-48CF-B3CE-C19108F8DEAF Q41436576-EE0F69F6-4BD3-46FA-BE64-A8844A90A9EA Q46641718-5E70C1A4-FA64-401A-BA42-58B42108F7A8 Q50587585-E629B6DE-4EDF-4706-94BE-1B2B129F5DD4

P2860

Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity.

http://www.wikidata.org/entity/Q31009736

description

1992 nî lūn-bûn

@nan

1992 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

1992 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

1992年の論文

@ja

1992年論文

@yue

1992年論文

@zh-hant

1992年論文

@zh-hk

1992年論文

@zh-mo

1992年論文

@zh-tw

1992年论文

@wuu

name

Intracellular availability of ...... otides for antisense activity.

@ast

Intracellular availability of ...... otides for antisense activity.

@en

type

label

Intracellular availability of ...... otides for antisense activity.

@ast

Intracellular availability of ...... otides for antisense activity.

@en

prefLabel

Intracellular availability of ...... otides for antisense activity.

@ast

Intracellular availability of ...... otides for antisense activity.

@en

P1433

Q31009736-F7F20D4F-491E-409D-8006-5B9CD88A0B86

P1476

Q31009736-108C8307-1A48-45FA-9112-8744F5760E7F

P2093

Q31009736-7C286175-F33F-4E6D-BA67-5B50D23D3495

Q31009736-DFA8D890-A716-42F9-998F-0DD197EEE52F

P2860

Q31009736-0663EEE4-93CD-4928-8FD5-578F4F94533C

Q31009736-072C98BC-BE6C-4D8F-ACD0-5D6DC8822672

Q31009736-1A5D10B4-9D2D-4D5F-BB26-CA70FB2AE18D

Q31009736-24F9F9EF-B86C-4294-8B40-7126EB2C374F

Q31009736-25F9AD86-3047-43C7-A77B-8F1AC28FF3CE

Q31009736-293C9B3D-D197-494B-A36B-D43EF413FD11

Q31009736-2A7D8F17-F3F9-4D09-8823-190A5F8671F1

Q31009736-366DE6C7-75C9-43BD-A881-39C50843DB72

Q31009736-3CEA7B7F-92EF-430B-8F71-6F8DBAD025E2

Q31009736-775E32AB-3C60-4C7D-B277-5F1349E819F5

P304

Q31009736-EEA3D525-DCCF-437A-A467-9A22862CC384

P31

Q31009736-C382A874-628C-4C6D-B827-35430EC07EDC

P356

Q31009736-6F14B2D5-60C2-4057-8820-A5120FDAECE6

P407

Q31009736-AC1A3B21-5A0D-42A7-83DD-5C445103E989

P433

Q31009736-97889B69-A2E3-4A01-8358-7BADE993EE41

P478

Q31009736-8A2BC6D7-E9EA-4718-A4F4-6895246EEFA5

P577

Q31009736-36CCE8C2-E84B-4A86-A8E0-555B9C87A2B8

P5875

Q31009736-0636F12C-B70E-406F-A49B-83E58529D757

P698

Q31009736-A8706972-F2D0-42B5-B7BD-642D726B4F5C

P932

Q31009736-A6D82CE1-AD28-4039-8587-A3AD9FEF8AE6

P356

P1433

Nucleic Acids Research

P1476

Intracellular availability of ...... otides for antisense activity.

@en

P2093

Dritschilo A

http://www.w3.org/2001/XMLSchema#string

Thierry AR

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates

Highly specific inhibition of IGF-I-stimulated differentiation by an antisense oligodeoxyribonucleotide to myogenin mRNA. No effects on other actions of IGF-T

The stability, toxicity and effectiveness of unmodified and phosphorothioate antisense oligodeoxynucleotides in Xenopus oocytes and embryos.

Specific regulation of gene expression by antisense, sense and antigene nucleic acids.

Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA.

Mechanism of oligonucleotide uptake by cells: involvement of specific receptors?

Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides

Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA.

Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes).

Modified deoxyoligonucleotides stable to exonuclease degradation in serum.

P304

5691-5698

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NAR/20.21.5691

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

1992-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

21700251

http://www.w3.org/2001/XMLSchema#string

P698

1454532

http://www.w3.org/2001/XMLSchema#string

P932

334404

http://www.w3.org/2001/XMLSchema#string